FRANKLIN LAKES, N.J. (June 3, 2025) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD Vascular Access Management (VAM) has been awarded the Infusion Nurses Society (INS) Seal of Approval. This endorsement serves as a symbol of excellence granting recognition that VAM has met INS rigorous standards.

“BD has decades of experience in clinical excellence and innovation in vascular access care, partnering with hospitals to help reduce complications, improve patient outcomes and set new care standards,” said Eric Borin, worldwide president, Medication Delivery Solutions at BD. “Receiving the INS Seal of Approval underscores our dedication to providing high-quality, evidence-based solutions that enhance patient care and support health care providers. We are proud of the tangible difference BD VAM is making in hundreds of hospitals nationwide.”

Vascular access is a common but complex process in healthcare settings, with varying products, policies and practices across units and shifts. BD VAM is an integrated approach that partners with healthcare facilities to identify and address gaps in the vascular access process through comprehensive clinical assessments, evidence-based recommendations and robust training programs.

Raleigh General Hospital (RGH) in Beckley, W.Va. is among the many hospitals that have successfully implemented a BD VAM initiative. This initiative has significantly improved patient outcomes, streamlined hospital operations and empowered nursing staff to set a new standard for vascular access care.

“The BD VAM program has been a game-changer for our hospital,” said Eric Flynn, RN, BSN, Director of Critical Care/Vascular Access at Raleigh General Hospital. “The formation of the Vascular Access Team and the implementation of evidence-based protocols have not only improved patient outcomes but also empowered our nursing staff to take ownership of their roles. This cultural shift has been transformative, and we are proud of the positive impact it has had on our patients and providers.”

As the global leader in vascular access solutions, BD is committed to advancing the standard of care for IV therapy for patients and health care providers. BD VAM is designed to help reduce the risk of vascular access-related complications, improve clinical and economic outcomes and increase patient satisfaction, empowering facilities to move closer to the vision of a “one-stick patient experience.” Supported by a clinical team of more than 80 vascular access specialists, many with VA-BC™ and CRNI® certifications, and the industry’s most comprehensive portfolio, BD has partnered with nearly half of the Top 100 Hospitals from the 2024 Fortune/PINC AI Top Hospital List^* and helped more than 900 facilities better understand their vascular access landscape.

For more information about BD Vascular Access Management, visit www.bd.com/vam.

*Inclusive of all BD VAM assessments conducted since 2017

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:                                                                                                      Investors:

Alyssa Kretlow                                                                                         Adam Reiffe
BD Public Relations                                                                                Sr. Director, Investor Relations
551.238.4391                                                                                                               201.847.6927         alyssa.kretlow@bd.com                                                                                                 adam.reiffe@bd.com